Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

Reshma Kewalramani’s journey to become the first female CEO of a large, public U.S. biotechnology company after immigrating ...

Zacks Research has upped the financial bar for Vertex Pharmaceuticals, boosting its 2026 earnings forecast from $16.18 to $16 ...

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain ...

Vertex Pharmaceuticals slipped 1.41% to close at $475.49, managing to outperform a much gloomier market where the S&P 500 nose-dived 3.46%. Despite the drop, Vertex flexed its resilience, outpacing ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective increased by Bank of America from $555.00 to $567.00 in a research note issued on Monday,Benzinga reports.

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against ...